TD Cowen started coverage on shares of Septerna (NASDAQ:SEPN – Free Report) in a research note published on Tuesday morning, Marketbeat.com reports. The brokerage issued a buy rating on the stock.
Septerna Price Performance
SEPN stock opened at $21.79 on Tuesday. Septerna has a twelve month low of $18.62 and a twelve month high of $26.34.
Insider Buying and Selling
In other Septerna news, major shareholder Rock Ventures V. L.P. Third purchased 370,500 shares of the business’s stock in a transaction on Monday, October 28th. The stock was acquired at an average price of $18.00 per share, with a total value of $6,669,000.00. Following the acquisition, the insider now directly owns 6,215,591 shares of the company’s stock, valued at $111,880,638. This trade represents a 6.34 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
About Septerna
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
Featured Stories
- Five stocks we like better than Septerna
- Business Services Stocks Investing
- Why Palo Alto Networks’ Multi-Year Uptrend Is Far From Over
- What is the Euro STOXX 50 Index?
- 3 Rock-Solid Buying Opportunities in the Market Right Now
- Insider Trades May Not Tell You What You Think
- TJX Companies Stock Poised to Hit a New High This Year
Receive News & Ratings for Septerna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Septerna and related companies with MarketBeat.com's FREE daily email newsletter.
